NervGen Pharma Corp. (TSX.V: NGEN) (OTCQX: NGENF) Starts Presentation at The LD 500
NervGen Pharma Corp. (TSX.V: NGEN) (OTCQX: NGENF) is restoring life's potential by creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis and Alzheimer's disease. NervGen's platform technology targets protein tyrosine phosphatase sigma ("PTPσ"), a neural receptor that impedes nerve repair. Inhibition of the PTPσ receptor has been shown to promote regeneration and remyelination of damaged nerves, as well as improvement of nerve function in animal models for various medical conditions. For more information, visit the company's website at www.nervgen.com About The LD 500…







